Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 9855318 Fusion proteins

Patent 9855318 was granted and assigned to Eli Lilly and Company on January, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Jonathan Wesley Day0

Andrew Ihor Korytko0

Craig Duane Dickinson0

David Bruce Baldwin0

Gregory Alan Lazar0

John Michael Beals0

Date of Patent

January 2, 2018

0

Patent Application Number

151405190

Date Filed

April 28, 2016

0

Patent Citations Received

US Patent 11919935 Ultra-long acting insulin-Fc fusion proteins and methods of use

0

US Patent 11667689 Insulin-Fc fusion proteins and methods of use to treat cancer

0

US Patent 11673934 Ultra-long acting insulin-Fc fusion proteins and methods of use

0

US Patent 11707517 Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use

0

US Patent 11773151 Ultra-long acting insulin-Fc fusion proteins and methods of use

Patent Primary Examiner

Cherie M Stanfield

0

Patent abstract

The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9855318 Fusion proteins

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool